AmoyDx® PD-L1 (E1L3N) Assay
Multi-Platform Compatibility
PPA: Positive Percent Agreement; NPA: Negative Percent Agreement; OPA: Overall Percent Agreement
Excellent Concordance
CDx Assay A is a commercial IHC assay using recombinant mouse monoclonal antibody; CDx Assay B is a commercial IHC assay using recombinant rabbit monoclonal antibody
AmoyDx PD-L1 (E1L3N) assay is a reliable and cost-effective way to evaluate PD-L1 status in multiple tumor types
A comprehensive pan-tumor analysis of PD-L1 using AmoyDx PD-L1 (E1L3N) assay
GC/GEJ: Gastric/gastroesophageal junction cancer, CRC: Colorectal cancer, NSCLC: Non-small cell lung cancerSource: published at ASCO 2023. DOI: 10.1200/JCO.2023.41.16_suppl.2656
Specifications
Publications
1. Liu, X., Zhang, X., Liu, C. et al. Immune and inflammation: related factor alterations as biomarkers for predicting prognosis and responsiveness to PD-1 monoclonal antibodies in cervical cancer. Discov Onc 13, 96 (2022).
2. Xu, Y., Huang, Z., Fang, J., Liu, A., Lu, H., Yu, X., Chen, K., Xu, X., Ma, X., Shi, W., Kim, Y., Hakozaki, T., Addeo, A., Shen, Y., Li, S., & Fan, Y. (2022). Tolerability, safety, and preliminary antitumor activity of fuzuloparib in combination with SHR-1316 in patients with relapsed small cell lung cancer: a multicenter, open-label, two-stage, phase Ib trial. Translational Lung Cancer Research, 11(6), 1069-1078.
3. Ren, Shengxiang et al. Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial. Journal of Thoracic Oncology, Volume 17, Issue 4, 544 - 557.
4. Jiang, T., Chen, J., Xu, X. et al. On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial. Mol Cancer 21, 4 (2022).